

7 May 2024

## Botanix Webinar – Registration Information

**Philadelphia PA and Perth Australia, 7 May 2024:** Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), announces today it will be hosting a webinar on Wednesday 8 May at 10:30am AEST (Sydney/Melbourne) / 8:30am AWST (Perth) to provide a comprehensive update on its commercial launch plans and market insights, as it nears planned approval of *Sofdra*<sup>TM</sup>.

The call will be hosted by Executive Chairman, Vince Ippolito and Chief Executive Officer, Dr Howie McKibbin, along with key members of the newly expanded commercial team, including guest Lisa Pieretti, the Executive Director of the International Hyperhidrosis Society.

Interested participants need to register before the webinar using the link below and dial in details will be sent in return.

### Webinar Details

**Date:** Wednesday, 8 May 2024

**Time:** 10:30am AEST (Sydney/Melbourne), 8:30am AWST (Perth)

**To register:** [https://us02web.zoom.us/webinar/register/WN\\_mzSgKfFpQzyVLU16fe\\_SNw](https://us02web.zoom.us/webinar/register/WN_mzSgKfFpQzyVLU16fe_SNw)

**Dial in details:** Will be sent to you directly upon registration

Release authorised by

**Vince Ippolito**

President and Executive Chairman

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis through FDA approval. FDA accepted the resubmission of the NDA for *Sofdra* in January 2024 as a complete response and confirmed a target approval timing for late June 2024. *Sofdra* is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical development for range of other dermatology conditions. To learn more please visit: <http://www.botanixpharma.com/>

**For more information, please contact:**

**General enquiries**

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

**Investor enquiries**

Hannah Howlett

WE Communications

P: +61 450 648 064

[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

**Media enquiries**

Haley Chartres

H^CK

P: +61 423 139 163

[haley@hck.digital](mailto:haley@hck.digital)